PRESS RELEASE

PRESS RELEASE

View printer-friendly version << Back

Novavax to Report Second Quarter 2010 Financial Results on August 6, 2010

ROCKVILLE, Md., July 30, 2010 /PRNewswire via COMTEX/ --

Novavax, Inc. (Nasdaq: NVAX) announced today that Dr. Rahul Singhvi, President & Chief Executive Officer, and members of senior management will provide a corporate update and review of second quarter 2010 financial results via a webcast and conference call on Friday, August 6, 2010, at 10:00 a.m. Eastern time.

To access the live audio webcast of the conference call, or the subsequent archived recording, visit the "Investors/Events" section of the company's website at www.novavax.com. Alternatively, callers may participate in the conference call by dialing 1-877-212-6076 (domestic) or 1-707-287-9331 (international). Webcast and telephone replays of the conference call will be available shortly after the completion of the call. To access the replay, callers should dial 1-800-642-1687 (domestic) or 1-706-645-9291 (international) and use passcode 89793634.

About Novavax, Inc.

Novavax, Inc. is a clinical-stage biopharmaceutical company creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology. The company produces potent VLP-based recombinant vaccines utilizing new and efficient manufacturing approaches. Novavax is committed to using its VLP technology to create country-specific vaccine solutions. The company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company's website: www.novavax.com.

SOURCE Novavax, Inc.

This site uses cookies and similar technologies to provide you with our services, enhance the performance and functionality of our services, and analyze the use of our products and services. By clicking ‘Accept’ you are indicating your consent for us to place these cookies. For more information, please read our Privacy Policy or manage your cookie settings.

Accept